Meagan Medical Deploys StudyManager Evolve for New Clinical Study
StudyManager today announced that Meagan Medical, Inc., a clinical research and product development company, has deployed StudyManager Evolve software to manage its latest clinical study.
“We are seeing more and more Evolve interest in the medical device market and are pleased that our Evolve software will help play a key role in Meagan Medical’s study,” said Jeff West, Director, Professional Services, StudyManager. “ It’s been exciting to work with the Meagan Medical team from startup, helping ensure the study stayed on track.”
Evolve's Web-based interface integrates clinical trial management and electronic data capture tools. These features are extremely scalable, and can be used together seamlessly or independently. Evolve enables users to create a single, centralized and secure location for key study information, simplifying study operations and enhancing team efficiency.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
